ÂÜÀòÂÒÂ×

Alison Lawton is a seasoned leader in the biotechnology sector, currently serving as the Chair of the Board of Directors at Dianthus Therapeutics, Inc. Since March 2022, Alison has been a Board Member at BlueRock Therapeutics and has held various board positions at X4 Pharmaceuticals, ProQR Therapeutics NV, and Aeglea BioTherapeutics. Additionally, Alison served as Chair at Magenta Therapeutics until September 2023 and held the role of President & CEO at Kaleido Biosciences from December 2017 to December 2020. Alison's extensive experience includes board memberships at Verastem and a previous role at Magenta Therapeutics. Alison obtained a BSc Hons in Pharmacology from King's College London between 1981 and 1984.